Lymphoproliferative Disorders
"Lymphoproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
| Descriptor ID |
D008232
|
| MeSH Number(s) |
C15.604.515 C20.683.515
|
| Concept/Terms |
Lymphoproliferative Disorders- Lymphoproliferative Disorders
- Disorder, Lymphoproliferative
- Disorders, Lymphoproliferative
- Lymphoproliferative Disorder
X-Linked Lymphoproliferative Disorder- X-Linked Lymphoproliferative Disorder
- Disorder, X-Linked Lymphoproliferative
- Disorders, X-Linked Lymphoproliferative
- Lymphoproliferative Disorder, X-Linked
- Lymphoproliferative Disorders, X-Linked
- X Linked Lymphoproliferative Disorder
- X-Linked Lymphoproliferative Disorders
- Epstein-Barr Virus Infection, Familial Fatal
- Epstein Barr Virus Infection, Familial Fatal
- Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males
- Epstein Barr Virus Induced Lymphoproliferative Disease In Males
- Familial Fatal Epstein-Barr Infection
- Familial Fatal Epstein Barr Infection
- Immunodeficiency 5
- Immunodeficiency 5s
- Duncan's Syndrome
- Lymphoproliferative Disease, X-Linked
- Disease, X-Linked Lymphoproliferative
- Diseases, X-Linked Lymphoproliferative
- Lymphoproliferative Disease, X Linked
- Lymphoproliferative Diseases, X-Linked
- X-Linked Lymphoproliferative Diseases
- Lymphoproliferative Syndrome, X-Linked, 1
- Purtilo Syndrome
- Purtilo Syndromes
- Syndrome, Purtilo
- Syndromes, Purtilo
- X-Linked Lymphoproliferative Disease
- X Linked Lymphoproliferative Disease
- X-Linked Lymphoproliferative Syndrome
- Lymphoproliferative Syndrome, X-Linked
- Lymphoproliferative Syndromes, X-Linked
- Syndrome, X-Linked Lymphoproliferative
- Syndromes, X-Linked Lymphoproliferative
- X Linked Lymphoproliferative Syndrome
- X-Linked Lymphoproliferative Syndromes
- Duncan Disease
- Disease, Duncan
- Immunodeficiency, X-Linked Progressive Combined Variable
- Immunodeficiency, X Linked Progressive Combined Variable
|
Below are MeSH descriptors whose meaning is more general than "Lymphoproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Lymphoproliferative Disorders".
This graph shows the total number of publications written about "Lymphoproliferative Disorders" by people in this website by year, and whether "Lymphoproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 5 | 1 | 6 |
| 1998 | 6 | 1 | 7 |
| 1999 | 1 | 1 | 2 |
| 2001 | 3 | 2 | 5 |
| 2002 | 2 | 0 | 2 |
| 2003 | 3 | 1 | 4 |
| 2004 | 4 | 0 | 4 |
| 2005 | 4 | 1 | 5 |
| 2006 | 3 | 2 | 5 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 5 | 2 | 7 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 1 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 4 | 1 | 5 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 3 | 5 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoproliferative Disorders" by people in Profiles.
-
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. JAMA. 2025 Oct 21; 334(15):1339-1348.
-
Navigating Epstein-Barr Virus (EBV) and Post-Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Liver Transplantation: Current Knowledge and Strategies for Treatment and Surveillance. Viruses. 2025 02 13; 17(2).
-
EBV and post-transplant lymphoproliferative disorder: a complex relationship. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):728-735.
-
A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Res. 2024 07 02; 84(13):2060-2072.
-
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood Adv. 2024 03 12; 8(5):1116-1127.
-
Real-world experience in older patients with diffuse large B-cell lymphoma treated in Latin America: A study by the Latin American study group of lymphoproliferative disorders (GELL). J Geriatr Oncol. 2023 09; 14(7):101565.
-
High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2022 01 25; 6(2):452-459.
-
Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
-
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells. Am J Transplant. 2021 10; 21(10):3465-3471.
-
HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease. Science. 2020 07 10; 369(6500):202-207.